Century Therapeutics (IPSC) Depreciation & Amortization (CF) (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $3.0 million in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 6.74% year-over-year to $3.0 million in Q1 2026; TTM through Mar 2026 was $12.9 million, a 3.11% decrease from a year earlier, with the FY2025 full-year figure at $13.1 million, down 1.53% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $3.0 million, down from $3.6 million in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for IPSC reached as high as $3.6 million in Q4 2023 and fell as low as $1.2 million in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $3.0 million across 5 years, with a median of $3.2 million in 2025.
• Across the five-year window, Depreciation & Amortization (CF) jumped 170.03% in 2022 and decreased 7.54% in 2025, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $2.8 million in 2022, then increased by 25.16% to $3.6 million in 2023, then retreated by 6.59% to $3.3 million in 2024, then gained by 6.99% to $3.6 million in 2025, then slipped by 15.38% to $3.0 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $3.0 million in Q1 2026, $3.6 million in Q4 2025, and $3.1 million in Q3 2025.